Annual Secretarial Compliance Certificate 31-03-2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek has filed its Annual Secretarial Compliance Report for FY25, which flags several governance gaps. The company did not reappoint three independent directors after their term expired, has not fully updated its website, and is yet to finalize key policies on grievance redressal, vigil mechanism, and related party transactions. It also failed to maintain the Structured Digital Database required under insider trading rules, and three independent directors lack valid registration certificates from the Indian Institute of Corporate Affairs. More seriously, the report discloses a Rs. 203.02 crore penalty imposed by the Enforcement Directorate on December 30, 2024 under FEMA 2000 related to a past GDR issue, along with a pending Rs. 38 lakh SEBI penalty from June 2022 for the same matter, with SEBI having frozen the company's bank and Demat accounts pending the outcome of its SAT appeal.
This is a materially negative disclosure for shareholders. The Rs. 203 crore ED penalty and frozen bank/Demat accounts create serious liquidity and operational risks, while repeated governance lapses raise concerns about board oversight. Investors should track the SAT hearing (scheduled July 27, 2025) and the Appellate Tribunal matter, as outcomes could significantly affect the company's financial position and stock price.